

An overview of precision oncology basket and umbrella

Ca-A Cancer Journal for Clinicians

70, 125-137

DOI: [10.3322/caac.21600](https://doi.org/10.3322/caac.21600)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 2020, 15, e0237802.	2.5	223
2	What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. Cancer, 2020, 126, 5022-5029.	4.1	9
3	Emerging role of long noncoding RNA-encoded micropeptides in cancer. Cancer Cell International, 2020, 20, 506.	4.1	41
4	Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy. ACS Combinatorial Science, 2020, 22, 669-700.	3.8	65
5	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	4.1	46
6	Is it accurate to classify ALS as a neuromuscular disorder?. Expert Review of Neurotherapeutics, 2020, 20, 895-906.	2.8	12
7	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.7	3
8	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155
9	Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Annals of Hematology, 2020, 99, 1161-1176.	1.8	9
10	The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases. Allergy International, 2021, 70, 266-268.	3.3	7
11	A Perspective of Epigenetic Regulation in Radiotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 624312.	3.7	19
12	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	7.7	14
13	Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. Pharmacoeconomics, 2021, 39, 771-788.	3.3	24
14	Precision oncology in metastatic colorectal cancer â€” from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	27.6	113
16	Randomised trials at the level of the individual. The Lancet Global Health, 2021, 9, e691-e700.	6.3	11
17	Precision Oncology. Advances in Oncology, 2021, 1, 97-112.	0.2	0
18	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. Radiation Oncology, 2021, 16, 95.	2.7	5
20	Recruitment, outcomes, and toxicity trends in phase I oncology trials: Sixâ€™year experience in a large institution. Cancer Reports, 2021, , e1465.	1.4	1

#	ARTICLE	IF	CITATIONS
21	Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. <i>Journal of Genetics and Genomics</i> , 2021, 48, 540-551.	3.9	19
22	An Overview of Phase 2 Clinical Trial Designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 22-29.	0.8	11
23	Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 659113.	2.8	4
24	Primary signet ring cell histology does not portend worse survival for early stage lung cancer following lobectomy. <i>Asian Cardiovascular and Thoracic Annals</i> , 2021, , 021849232110459.	0.5	1
25	Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 83-94.	3.6	35
26	Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 410-415.	2.0	5
27	Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck. <i>Oral Oncology</i> , 2021, 121, 105436.	1.5	3
28	Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. <i>Lancet Oncology, The</i> , 2021, 22, e430-e434.	10.7	24
29	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.6	5
30	Triple-negative breast cancer therapy: Current and future perspectives (Review). <i>International Journal of Oncology</i> , 2020, 57, 1245-1261.	3.3	196
31	Liquid Biopsies for Molecular Biology-Based Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11267.	4.1	4
32	Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. <i>Cancers</i> , 2021, 13, 5182.	3.7	5
33	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1611-1624.	3.0	7
35	BuqiTongluo Granule for Ischemic Stroke, Stable Angina Pectoris, Diabetic Peripheral Neuropathy with Qi Deficiency and Blood Stasis Syndrome: Rationale and Novel Basket Design. <i>Frontiers in Pharmacology</i> , 2021, 12, 764669.	3.5	6
36	Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers. <i>Frontiers in Public Health</i> , 2021, 9, 754482.	2.7	2
37	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. <i>Cancers</i> , 2021, 13, 5660.	3.7	16
38	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	2.0	0
39	Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. <i>Frontiers in Medicine</i> , 2021, 8, 818647.	2.6	7

#	ARTICLE	IF	CITATIONS
40	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. Expert Review of Anticancer Therapy, 2022, 22, 275-287.	2.4	3
41	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	12.8	78
42	Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nature Communications, 2022, 13, 873.	12.8	13
43	Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health, 2022, 25, 1371-1380.	0.3	6
44	Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. International Journal of Molecular Sciences, 2022, 23, 3012.	4.1	6
45	Therapeutic impact and routine application of next-generation sequencing: A single institute study. Biomedical Reports, 2022, 16, 33.	2.0	0
46	Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE, 2022, 17, e0264138.	2.5	100
47	Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine. Current Oncology Reports, 2022, 24, 1035-1044.	4.0	2
48	Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study. BMC Medical Research Methodology, 2021, 21, 282.	3.1	0
49	Precision diagnostics in cancer: Predict, prevent, and personalize. Progress in Molecular Biology and Translational Science, 2022, , 39-56.	1.7	1
50	Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open, 2022, 12, e052926.	1.9	11
51	Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors. Cancers, 2022, 14, 2457.	3.7	8
52	Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer, 0, , .	6.4	2
53	Treatment of biliary tract carcinoma over the last 30 years. BioScience Trends, 2022, 16, 189-197.	3.4	2
54	Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. BMJ, The, 0, , e067745.	6.0	1
55	A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach. Frontiers in Medicine, 0, 9, .	2.6	1
56	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	5.5	4
57	Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. Journal of the International AIDS Society, 2022, 25, .	3.0	6

#	ARTICLE	IF	CITATIONS
59	Translational cancer research in India: Challenges and promises. Journal of Cancer Research and Therapeutics, 2023, 19, 526-529.	0.9	1
60	Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients. Cancers, 2022, 14, 4156.	3.7	5
61	Clinical trial design in the era of precision medicine. Genome Medicine, 2022, 14, .	8.2	68
62	Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment. Genome Medicine, 2022, 14, .	8.2	3
63	Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 2022, 23, .	1.6	4
64	Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clinical Cancer Research, 2023, 29, 401-409.	7.0	4
65	Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?. Cytotherapy, 2023, 25, 341-352.	0.7	11
66	Design and analysis of umbrella trials: Where do we stand?. Frontiers in Medicine, 0, 9, .	2.6	2
67	Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	54
68	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	3.7	11
69	A perspective on oligonucleotide therapy: Approaches to patient customization. Frontiers in Pharmacology, 0, 13, .	3.5	23
70	Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Cancer Medicine, 2023, 12, 6170-6181.	2.8	3
71	<i>WT1</i> and <i>DNMT3A</i> play essential roles in the growth of certain patient AML cells in mice. Blood, 0, , .	1.4	0
72	A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. European Journal of Cancer, 2023, 178, 227-233.	2.8	3
73	Current Status of Natural Products/siRNA Coâ€Delivery for Cancer Therapy. ChemistrySelect, 2022, 7, .	1.5	0
74	Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker. Frontiers in Genetics, 0, 13, .	2.3	0
75	Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany. Value in Health, 2023, 26, 854-864.	0.3	2
77	First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. Anti-Cancer Drugs, 2023, 34, 294-301.	1.4	0

#	ARTICLE	IF	CITATIONS
78	Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. <i>BMJ Evidence-Based Medicine</i> , 2024, 29, 1-5.	3.5	11
79	RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study. , 0, 3, .		1
80	Randomized controlled trials and alternative study designs in surgical oncology. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1331-1340.	1.0	1
81	Biologicals and small molecules as target-specific cancer chemotherapeutic agents. , 2023, , 615-646.		0
82	Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice. <i>Lancet Oncology</i> , The, 2023, 24, e197-e206.	10.7	2
83	Understanding inequities in precision oncology diagnostics. <i>Nature Cancer</i> , 2023, 4, 787-794.	13.2	3
84	Drug screening at single-organoid resolution via bioprinting and interferometry. <i>Nature Communications</i> , 2023, 14, .	12.8	10
85	Drug Target Identification in Triple Negative Breast Cancer Stem Cell Pathways: A Computational Study of Gene Regulatory Pathways Using Boolean Networks. <i>IEEE Access</i> , 2023, 11, 56672-56690.	4.2	2
86	Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 745.	2.5	0
88	Targeting shared molecular etiologies to accelerate drug development for rare diseases. <i>EMBO Molecular Medicine</i> , 2023, 15, .	6.9	4
89	The role of clinical imaging in oncology drug development: progress and new challenges. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	0
91	Introduction to traditional Chinese medicine (TCM) regulatory science for TCM high-quality development. <i>Chinese Science Bulletin</i> , 2023, , .	0.7	0
92	Accelerating the development of a psychological intervention to restore treatment decision-making capacity in patients with schizophrenia-spectrum disorder: a study protocol for a multi-site, assessor-blinded, pilot Umbrella trial (the DEC:IDES trial). <i>Pilot and Feasibility Studies</i> , 2023, 9, .	1.2	1
93	Co-delivery of exemestane and thymoquinone via nanostructured lipid carriers for efficient breast cancer therapy. <i>Journal of Drug Delivery Science and Technology</i> , 2023, , 104892.	3.0	0
94	Inflammation across tissues: can shared cell biology help design smarter trials?. <i>Nature Reviews Rheumatology</i> , 2023, 19, 666-674.	8.0	2
96	Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study. <i>Hepatic Oncology</i> , 2023, 10, .	4.2	0
97	Regulatory Qualification of a Cross-Disease Digital Measure: Benefits and Challenges from the Perspective of IMI Consortium IDEA-FAST. <i>Digital Biomarkers</i> , 2023, 7, 132-138.	4.4	1
99	Decision making in clinical trials: Interim analyses, innovative design, and biomarkers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2023, 9, .	3.7	0

#	ARTICLE	IF	CITATIONS
100	Precision Nutrition and Cancer. , 2024, , 277-298.		1
101	Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. Journal of Clinical Oncology, 2024, 42, 348-357.	1.6	4
102	Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity. Frontiers in Oncology, 0, 13, .	2.8	0
103	Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems. Pharmaceutics, 2023, 15, 2623.	4.5	0
104	Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges. Frontiers in Pharmacology, 0, 14, .	3.5	0
105	Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer, 0, , .	4.1	0
106	tRNA therapeutics for genetic diseases. Nature Reviews Drug Discovery, 2024, 23, 108-125.	46.4	1
107	Cancer management in terms of precision oncology. Oral Oncology, 2024, 148, 106658.	1.5	0
108	Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges. Frontiers in Oncology, 0, 13, .	2.8	0
109	Practical Considerations for Oncogenic Fusion Detection and Reporting in Solid Tumors. journal of applied laboratory medicine, The, 2024, 9, 116-123.	1.3	0
110	The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?. Pediatric Rheumatology, 2023, 21, .	2.1	0
111	Pediatric oncology drug development and dosage optimization. Frontiers in Oncology, 0, 13, .	2.8	0
112	Omics-based molecular classifications empowering in precision oncology. Cellular Oncology (Dordrecht), 0, , .	4.4	0
113	Clinical data mining: challenges, opportunities, and recommendations for translational applications. Journal of Translational Medicine, 2024, 22, .	4.4	0
114	Precision Medicine. Advances in Medical Diagnosis, Treatment, and Care, 2024, , 257-280.	0.1	0
115	New clinical trial design in precision medicine: discovery, development and direction. Signal Transduction and Targeted Therapy, 2024, 9, .	17.1	0
116	Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives. , 2024, , 335-377.		0